SEC Info - Nymox Pharmaceutical Corp - ‘20-F’ for 12/31/15

SEC Info℠

Home

Help

Please Sign In

Nymox Pharmaceutical Corp – ‘20-F’ for 12/31/15 – ‘EX-13.A’

On: Wednesday, 3/30/16, at 9:42pm ET · As of: 3/31/16 · For: 12/31/15 · Accession #: 1176256-16-495 · File #: 1-12033

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 3/31/16  Nymox Pharmaceutical Corp         20-F       12/31/15    8:1.2M                                   e3 Fil… Computershare/FA

Annual Report by a Foreign Private Issuer — Form 20-F
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 20-F        Annual Report for the Fiscal Year Ended December    HTML    836K 
                          31, 2015                                               
 2: EX-4.W      Common Stock Private Purchase Agreement Dated       HTML    105K 
                          November 1, 2013                                       
 3: EX-4.X      6% Secured Convertible Note Dated December 16,      HTML     54K 
                          2014                                                   
 4: EX-4.Y      Response Letter From Kpmg in the Corporation's 6-K  HTML     31K 
                          Dated July 16, 2015                                    
 7: EX-13.A     Sox Section 906 CEO Certification                   HTML      7K 
 8: EX-13.B     Sox Section 906 CFO Certification                   HTML      7K 
 5: EX-12.A     Sox Section 302 CEO Certification                   HTML     11K 
 6: EX-12.B     Sox Section 302 CFO Certification                   HTML     12K

EX-13.A — Sox Section 906 CEO Certification

This Exhibit is an HTML Document rendered as filed. [ Alternative Formats ]

Exhibit 13 (a)

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period ended December 31, 2015 of Nymox Pharmaceutical Corporation and filed with the Securities and Exchange Commission, fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934 and the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Nymox Pharmaceutical Corporation

Date: March 30, 2016

/s/ Paul Averback, MD
Paul Averback, MD
President and Chief Executive Officer
Nymox Pharmaceutical Corporation

Dates Referenced Herein and Documents Incorporated by Reference

This ‘20-F’ Filing	Date	Other Filings

Filed as of:	3/31/16	6-K
Filed on:	3/30/16
For Period End:	12/31/15	6-K, 6-K/A
		List all Filings

4 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/30/22  Nymox Pharmaceutical Corp.        20-F       12/31/21  106:6M                                     Pubco Reporting … Inc/FA
 3/29/21  Nymox Pharmaceutical Corp.        20-F       12/31/20  103:4.4M                                   Pubco Reporting … Inc/FA
11/01/16  SEC                               UPLOAD¶     9/27/17    1:126K Nymox Pharmaceutical Corp.
 9/21/16  SEC                               UPLOAD¶     9/27/17    1:153K Nymox Pharmaceutical Corp.

↑Top

Filing Submission 0001176256-16-000495 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)